Marker Therapeutics (MRKR) Competitors $1.92 -0.01 (-0.31%) As of 01/30/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MRKR vs. INZY, EPRX, IMAB, XFOR, SCLX, IMUX, GNLX, SKYE, ENTX, and ALTSShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Inozyme Pharma (INZY), Eupraxia Pharmaceuticals (EPRX), I-Mab (IMAB), X4 Pharmaceuticals (XFOR), Scilex (SCLX), Immunic (IMUX), Genelux (GNLX), Skye Bioscience (SKYE), Entera Bio (ENTX), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Inozyme Pharma Eupraxia Pharmaceuticals I-Mab X4 Pharmaceuticals Scilex Immunic Genelux Skye Bioscience Entera Bio Janone Marker Therapeutics (NASDAQ:MRKR) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Does the MarketBeat Community favor MRKR or INZY? Marker Therapeutics received 17 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 87.30% of users gave Inozyme Pharma an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Inozyme PharmaOutperform Votes5587.30% Underperform Votes812.70% Do analysts rate MRKR or INZY? Marker Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 889.58%. Inozyme Pharma has a consensus target price of $18.33, suggesting a potential upside of 1,155.71%. Given Inozyme Pharma's higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in MRKR or INZY? 22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 17.4% of Marker Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor MRKR or INZY? In the previous week, Marker Therapeutics and Marker Therapeutics both had 2 articles in the media. Marker Therapeutics' average media sentiment score of 0.44 beat Inozyme Pharma's score of 0.11 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Marker Therapeutics Neutral Inozyme Pharma Neutral Is MRKR or INZY more profitable? Inozyme Pharma has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Inozyme Pharma's return on equity of -88.42% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% Inozyme Pharma N/A -88.42%-57.02% Which has more volatility and risk, MRKR or INZY? Marker Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Which has stronger earnings and valuation, MRKR or INZY? Marker Therapeutics has higher revenue and earnings than Inozyme Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$3.31M6.21-$8.24MN/AN/AInozyme PharmaN/AN/A-$71.17M-$1.56-0.94 SummaryInozyme Pharma beats Marker Therapeutics on 7 of the 13 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.56M$6.92B$5.61B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / Sales6.21351.361,216.4981.09Price / CashN/A65.4844.3437.71Price / Book1.225.335.134.73Net Income-$8.24M$157.56M$118.85M$225.42M7 Day Performance-10.28%2.05%1.40%0.75%1 Month Performance-38.26%2.62%7.53%3.61%1 Year Performance-58.62%9.59%26.68%21.42% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.1925 of 5 stars$1.92-0.3%$19.00+889.6%-56.0%$20.56M$3.31M0.0060Short Interest ↑INZYInozyme Pharma3.3196 of 5 stars$1.36flat$18.33+1,248.0%-73.6%$87.37MN/A-0.8750Short Interest ↑High Trading VolumeEPRXEupraxia Pharmaceuticals3.5384 of 5 stars$3.20+6.3%$9.00+181.3%N/A$87.30MN/A-4.4429Gap UpIMABI-Mab2.8601 of 5 stars$1.07-2.7%$8.00+647.7%-42.1%$87.21M$3.89M0.00380Short Interest ↑Gap DownXFORX4 Pharmaceuticals4.3243 of 5 stars$0.51+10.1%$3.50+589.5%-17.5%$86.57MN/A-5.6480Gap UpSCLXScilex3.7108 of 5 stars$0.45-4.3%$11.33+2,424.1%-73.7%$86.11M$46.74M-0.3180Gap DownIMUXImmunic3.7235 of 5 stars$0.95-3.4%$12.67+1,229.1%-15.7%$85.85MN/A-0.7770Short Interest ↓High Trading VolumeGNLXGenelux2.1725 of 5 stars$2.46-0.8%$18.25+641.9%-64.1%$84.97M$170,000.00-2.5910Positive NewsSKYESkye Bioscience1.6215 of 5 stars$2.63-3.6%$18.67+609.0%+19.4%$84.04MN/A0.0011News CoveragePositive NewsGap UpENTXEntera Bio2.4497 of 5 stars$2.34+4.9%$10.00+327.4%+167.8%$83.73M$130,000.00-9.0020Short Interest ↓News CoverageALTSJanoneN/A$5.95-0.2%N/AN/A$83.71M$7.11M0.00170Short Interest ↓Gap Up Related Companies and Tools Related Companies Inozyme Pharma Alternatives Eupraxia Pharmaceuticals Alternatives I-Mab Alternatives X4 Pharmaceuticals Alternatives Scilex Alternatives Immunic Alternatives Genelux Alternatives Skye Bioscience Alternatives Entera Bio Alternatives Janone Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRKR) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
